MHRA Inspection Success For Nottingham's Upperton Pharma Solutions

Upperton Pharma Solutions’ new pharmaceutical manufacturing facilities at Nottingham Science and Technology Park have successfully passed inspection by the UK Medicines and Healthcare products Regulatory Agency (MHRA).

A pharmaceutical contract development and manufacturing organisation (CDMO), Upperton Pharma Solutions moved to its new facilities on Nottingham Science and Technology Park from its previous headquarters at BioCity Nottingham in March 2018, as part of a planned expansion of its services.

The company has invested heavily in the new facilities both in terms of building enhancements and in the expansion of its processing and analytical capabilities.

The successful MHRA inspection provides Upperton Pharma Solutions with the necessary MHRA licenses for manufacture, downstream processing into capsules and tablets, as well as release of spray dried formulations of Biotherapeutics and small molecule APIs for clinical trials.

The company is also able to now develop pharmaceutical formulations for oral, nasal and pulmonary delivery right through from early feasibility studies to Phases I & II clinical manufacture, all from its Nottingham Science and Technology Park site.

Richard Johnson, CEO and Founder of Upperton Pharma Solutions, said: “We are absolutely delighted with the expansion of our capabilities in GMP clinical manufacturing and look forward to seeing our clients’ projects progress within Upperton, from early formulation development studies right through to clinical manufacture.

“The positive endorsement by the MHRA will enable a seamless transition from R&D to GMP manufacture within the organisation, ensuring that all of the project-specific knowledge and expertise developed in R&D will flow through to the GMP manufacturing processes.”

Paul Kelsall, Director of Clinical Trials Manufacturing commented: “This is a great opportunity for our business and is a result of our team’s commitment to achieve the targets and aspirations of our business. We are looking forward to working with our clients and offering services from early stage development through to clinical manufacture. These are exciting times for Upperton as we continue to move forward and expand our capabilities.”

To read more about Upperton Pharma Solutions’ GMP capabilities click here (http://www.upperton.com/cgmp).

About Upperton Pharma Solutions
At a time when the global CDMO market place is consolidating, Upperton Pharma Solutions remains as one of the few independent CDMO service providers with a specific focus on developing pharmaceutical dosage forms using its specialised spray drying capabilities. Upperton provides a range of integrated services to the pharmaceutical and biotech sectors around the world. The services include: early feasibility studies, formulation development for both small molecule APIs and Biotherapeutics for a range of final dosage forms and GMP manufacture of materials for Phase I & II clinical trials. Full analytical support, including ICH stability studies, is offered.

The company is a privately-owned organisation that has grown organically over almost 20 years and now employs 24 highly skilled personnel. Upperton Pharma Solutions has its headquarters in Nottingham, UK. For more information, visit upperton.com.